within Pharmacolibrary.Drugs.ATC.P;

model P03BX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P03BX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dibutylsuccinate is an organosuccinate compound previously used as an anthelmintic agent (anti-parasitic) primarily in veterinary medicine to treat infections caused by nematode worms. It is classified under the ATC code P03BX04. Dibutylsuccinate is not widely used or approved for human or veterinary therapy today, and there is limited recent information regarding its use, efficacy, or safety.</p><h4>Pharmacokinetics</h4><p>Since no primary literature or referenced pharmacokinetic studies are available for dibutylsuccinate in humans or animals, the pharmacokinetic parameters provided here are rough estimates based on general properties of small ester compounds used via oral administration in veterinary medicine for anthelmintic purposes.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=&quot;https://doi.org/10.1007/s40261-015-0320-8&quot;>10.1007/s40261-015-0320-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26334726/&quot;>https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Freedman, MD, &amp; Somberg, JC (1991). Pharmacology and pharmacokinetics of amiodarone. <i>Journal of clinical pharmacology</i> 31(11) 1061–1069. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1991.tb03673.x&quot;>10.1002/j.1552-4604.1991.tb03673.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1753010/&quot;>https://pubmed.ncbi.nlm.nih.gov/1753010</a></p></li><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2021). Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. <i>Pharmaceutical research</i> 38(8) 1345–1356. DOI:<a href=&quot;https://doi.org/10.1007/s11095-021-03078-w&quot;>10.1007/s11095-021-03078-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34341958/&quot;>https://pubmed.ncbi.nlm.nih.gov/34341958</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P03BX04;
